Effects of milk casein derived tripeptides on endothelial enzymes in vitro; a study with synthetic tripeptides.
In the fermentation of milk by certain lactic acid bacteria, casein is degraded into bioactive tripeptides shown to lower blood pressure in experimental animal models and in mildly hypertensive humans. This effect is suggested to result mainly in inhibition of angiotensin converting enzyme 1 (ACE-1).Due to the complexity of renin-angiotensin system (RAS), several other enzymes than ACE-1 can participate in the production of vasoactive components. Therefore, in the present study we investigated effects of tripeptides isoleucine-proline-proline (IPP), valine-proline-proline (VPP) and leucine-proline-proline (LPP) on some endothelial enzymes that are important in RAS or otherwise have a role in the endothelial function. The enzymes investigated were renin, chymase, neutral endopeptidase (NEP), prolyl oligopeptidase (POP), cathepsin G, endothelin converting enzyme 1 (ECE-1), and cyclooxygenase 1 and 2 (COX -1 and COX-2).The tripeptides inhibited prolyl oligopeptidase (POP) dose-dependently. IPP was the most potent inhibitor (IC50 486±95 µM). Contrary, cathepsin G was activated by IPP, VPP and LPP as well as the amino acids proline and isoleucine. The other investigated enzymes were not affected. Inhibition of POP and activation of cathepsin G do not explain the blood pressure lowering effects of the tripeptides. Thus the inhibition of ACE-1 remains the most plausible mechanism of the antihypertensive effects of the tripeptides.
Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland. aino.siltari@helsinki.fi
A
A
Siltari
A S
AS
Kivimäki
P I
PI
Ehlers
R
R
Korpela
H
H
Vapaatalo
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D019540:Area Under Curve; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D001794:Blood Pressure / Q000187:drug effects; D002364:Caseins / Q000737:chemistry / Q000494:pharmacology*; D056649:Cathepsin G / Q000037:antagonists & inhibitors; D053818:Chymases / Q000037:antagonists & inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D000072396:Endothelin-Converting Enzymes; D004730:Endothelium, Vascular / Q000201:enzymology*; D006801:Humans; D007700:Kinetics; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D015260:Neprilysin / Q000378:metabolism; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D000085822:Prolyl Oligopeptidases; D011480:Protease Inhibitors; D012083:Renin / Q000097:blood; D012697:Serine Endopeptidases / Q000378:metabolism; D000092502:Renin Inhibitors
D000806:Angiotensin-Converting Enzyme Inhibitors; D016282:Aspartic Acid Endopeptidases; D002364:Caseins; D056649:Cathepsin G; D053818:Chymases; D016861:Cyclooxygenase Inhibitors; D000072396:Endothelin-Converting Enzymes; D008666:Metalloendopeptidases; D015260:Neprilysin; D009842:Oligopeptides; D000085822:Prolyl Oligopeptidases; D011480:Protease Inhibitors; D012083:Renin; D012697:Serine Endopeptidases; D000092502:Renin Inhibitors; C000705287:PREPL protein, human; C000606923:ECE1 protein, human